**15. Combining immunotherapy with epigenetics in cancer treatment**

Immunotherapy arguably is one of the exciting new developments for the management of advanced human tumors, in particular the concept of immune checkpoint blockade [102–104]. Antibodies targeting PD-1, CTLA-4 and PD-L1 show robust responses in treatment of melanoma, and in high grade tumors. Although, these recent advances are very exciting and promising, however majority of the tumor patients including TNBC patients show little or no response at all to immune checkpoint therapy alone [105, 106].

Therefore raising an apparent question as to whether immunotherapy could work in combination with other therapies like immune checkpoint targeting agents to enhance the clinical response and efficiency of various sub types of cancers. Nevertheless, various clinical trials as like previously discussed are evolving while keeping in control the related toxicities [107].

Other combination strategies targeting immunotherapy in combination with chemotherapy as well targeted therapy approaches likely epigenetic therapy. As epigenetic therapy has been evidenced to strongly sensitize patients to immune checkpoint therapy.
